Boehringer Ingelheim Pharma GmbH & Co. KG Reports Findings in Psoriasis [Spesolimab Reduces Inflammation in Generalized Pustular Psoriasis: Molecular Characterisation of Flare Treatment in EFFISAYIL® 1]

Press/Media

Period25 Jul 2024

Media coverage

1

Media coverage

  • TitleBoehringer Ingelheim Pharma GmbH & Co. KG Reports Findings in Psoriasis [Spesolimab Reduces Inflammation in Generalized Pustular Psoriasis: Molecular Characterisation of Flare Treatment in EFFISAYIL® 1]
    Media name/outletDaily Veterinary News
    Country/TerritoryUnited States
    Date25/07/24
    PersonsMark Lebwohl
View all 1
View less